We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Beyond analysts' top -and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Merck & Co has a lower P/E than the aggregate P/E of 26.97 of the Pharmaceuticals industry. Ideally, one might believe that ...

The stock's rise snapped a three-day losing streak.

Merck (NYSE:MRK) entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this ...

The Dow Jones Industrial Average (DJIA) declined on Thursday despite many stocks on the index rising. Instead, a few major ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

MERCK & CO INC (MRK) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.